Safety and Pharmacokinetic Study of Anthrax Immune Globulin Derived From Human Serum
Safety and Pharmacokinetics of Anthrax Immune Globulin Intravenous (Human), NP-015, in Healthy Volunteers.
Sponsor: Department of Health and Human Services
Listed as NCT00448253, this PHASE1 trial focuses on Symptoms of Inhalational Anthrax and remains completed. Sponsored by Department of Health and Human Services, it has been updated 8 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Apr 2024 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Apr 2024 [monthly]
Completed PHASE1
-
Apr 2020 — Jan 2021 [monthly]
Completed PHASE1
▶ Show 3 earlier versions
-
Jun 2018 — Apr 2020 [monthly]
Completed PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1
First recorded
Jul 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Department of Health and Human Services
- Emergent BioSolutions
For direct contact, visit the study record on ClinicalTrials.gov .